Isomorphic Labs AI-designed drugs enter human clinical trials, marking pharmaceutical AI milestone

DeepMind spinoff Isomorphic Labs announced that AI-designed drugs are moving into human clinical trials, with president Max Jaderberg revealing a broad pipeline of new medicines. This milestone represents significant progress in AI applications for drug discovery beyond software domains.